Absci Corp ABSI
News
Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline
Absci to Participate in Upcoming Investor Conferences
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
Absci to Participate in Upcoming Investor Conferences
Healthcare stocks have become a haven for investors ditching tech
Absci Reports Data From Trial for Hair-Loss Treatment, Prices $100 Million Stock Offering
Absci Shares Fall on Wider 4Q Loss, Lower Revenue



